Eribulin mesylate injection composition and preparation method
By adding sodium metabisulfite and terema amino in the preparation of Ariblin methanesulfonate injection, combining a simple preparation process and high-pressure discharge method, the problems of cumbersome synthesis steps and poor thermal stability in the prior art are solved, and the problem of cumbersome synthesis steps and poor thermal stability in the prior art is achieved. The product's heat resistance and sterility guarantee significantly reduce adverse reactions and production costs.
Patent Information
- Application Number
- CN202111643900.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2021-12-29
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2041-12-29
AI Technical Summary
The synthesis steps of the existing Aribulin methanesulfonate injection are cumbersome, the structural thermal stability is poor, and there are many impurities that are easy to degrade, resulting in an increase in clinical adverse reactions and the inability to tolerate humid and heat sterilization process, affecting the aseptic guarantee.
Using a composition containing sodium metabisulfite and terematriol, overkilling is performed through a simple preparation process, using nitrogen or carbon dioxide as protective gas, filtration of the three-stage folding filter element and high-pressure discharge method to achieve wet heat of 121°C for 15 minutes Sterilization ensures product quality and sterility.
Improve the heat resistance and stability of Aribulin methanesulfonate injection, reduce adverse reactions, meet the sterility guarantee under high-temperature and autoclave sterilization conditions, and maintain product quality under long-term conditions, significantly improving clinical Security.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of pharmaceutical preparations, and mainly relates to an eribulin mesylate injection composition and a preparation method thereof. Background Art
[0002] The original developer of eribulin mesylate injection is Eisai Pharmaceutical. It was first launched in the United States in November 2010, and has since been sold in European countries and Japan. Eisai Pharmaceutical submitted an application for marketing approval of eribulin mesylate to China (JXHS1700048) on July 12, 2019 and obtained approval for marketing from the National Medical Products Administration (NMPA). It is the first single-agent chemotherapy drug used to improve the overall survival of patients with metastatic breast cancer, and is mainly used to treat metastatic breast cancer.
[0003]
[0004] Eribulin Mesylate
[0005] Molecular formula: C 40 H 59 NO 11 ·CH4O3S
[0006] Molecular weight: 826.00
[0007] According to the information published in the original patent CN105683198B, it was determined that the synthesis steps of the eribulin mesylate raw material are as long as 62 steps, the molecular weight is extremely large, and the structure contains 19 chiral centers. The thermal stability of the structure is poor, and there are many degradable impurities, which in turn leads to an increase in clinical adverse reactions.
[0008] In addition, according to the notice of the "Guidelines for Research and Verification of Sterilization and Aseptic Processes for Chemical Injections (Trial)" (No. 53 of 2020) published by the Drug Review Center of the State Drug Administration, the wet heat sterilization process for injections should give priority to the overkill method, that is, the sterilization process with an F0 (standard sterilization time) value greater than 12, and only when it is proved in theory and practice that even after adopting various feasible technical methods, the active ingredients of the drug still cannot tolerate the wet heat sterilization process, can a sterile production process with a lower sterility assurance level be selected. However, the domestic patent CN105640935A discloses that the preparation adopts 121°C and 15min. Although it meets the F0 value of about greater than 12, the preparation changes color after sterilization, and the sterilization parameters need to be reduced to ensure product quality, thereby reducing sterility assurance and bringing greater safety risks to the clinic.
[0009] In summary, the current formulation process of eribulin mesylate injection is prone to degradation and has a low level of sterility assurance, which in turn leads to increased clinical adverse reactions and patient intolerance. Summary of the invention
[0010] The object of the present invention is to provide an eribulin mesylate injection composition and a preparation method, which can tolerate overkilling, have good quality stability, low stress response of animals, simple production process operation, mature technology, easy control, low requirements on equipment and preparation conditions, low production cost, and are suitable for large-scale production of an eribulin mesylate injection composition and a preparation process, and the purpose is to reduce adverse reactions of dosage and improve the national medical level.
[0011] The present invention provides an eribulin mesylate injection composition and a preparation process that can tolerate overkill, which is characterized by comprising the following raw and auxiliary material components in parts by weight:
[0012]
[0013] The preparation process of the composition is as follows: taking a volume of 100 ml as an example, 0.03-0.07 g of sodium metabisulfite, 0.095-0.105 g of eribulin mesylate and 0.095-0.105 g of tromethamine are added to 90.00-95.00 g of water for injection, and after stirring and dissolving, a sodium hydroxide solution is used to adjust the pH of the mother liquor to 7.2-7.8, and water for injection is added to the full amount. Protective gas needs to be filled in the whole process of preparation, and finally filtering, filling, sterilizing, leak detection and packaging are performed.
[0014] The liquid preparation temperature in the composition preparation process is 20-30°C.
[0015] The protective gas in the composition preparation process includes nitrogen or carbon dioxide.
[0016] The sodium hydroxide concentration in the composition preparation process is 8% to 12%.
[0017] The filtration process in the preparation process of the composition is three-stage folded filter element filtration, and the filter element material is polyethersulfone or polypropylene.
[0018] The sterilization process of the composition preparation process is wet heat sterilization, and the parameters are 121° C. for 15 min.
[0019] The leak detection process of the composition preparation process is a high-voltage discharge method, and the parameters are a host speed of 300 to 400 pieces per minute, a station voltage of 17500V, and a station threshold of 827μA.
[0020] The glass bottle material used in the composition preparation process is a 2 mL colorless medium borosilicate glass tube injection bottle.
[0021] The rubber plug material used in the composition preparation process is a brominated butyl rubber plug for injection preparations.
[0022] Through research, the present invention unexpectedly found that after adding tromethamine and sodium pyrosulfite to the prescription, the preparation was sterilized at the terminal, and the liquid medicine did not change color, ensuring the sterility of the preparation, and the product quality also met the quality preparation requirements of injections. In addition, the preparation was compared with the 0-day product under long-term conditions for 24 months, and there was no significant change. At the same time, the preparation was subjected to animal experimental research, and it was determined that the hemolyticity, irritation and allergic reaction of the product were better than those of the original preparation.
[0023] Compared with the prior art, the present invention has the following advantages:
[0024] The present invention uses the prescription published in CN105640935A and the instructions for the original imported Halaven preparation produced by Eisai Co., Ltd. as comparative examples for comparison. The advantages and main overcomes of the present invention are as follows:
[0025] The eribulin mesylate injection composition prepared by the present invention can withstand excessive killing at 121°C for 15min (F0 is greater than 12), the preparation process is simple and controllable, and samples are retained under long-term conditions (30°C±2°C, 65%±5%RH). It is shown within 24 months that there is no impurity growth and all test items meet the requirements for injections. At the same time, with reference to the "Technical Guidance for Research on Drug Irritation, Allergy and Hemolysis" published by the Drug Review Center of the State Food and Drug Administration, with the original drug as the control, a hemolysis test, a guinea pig systemic active allergy test, a rat passive skin allergy test and a rabbit muscle irritation test are carried out, and the results show that the preparation prepared by the composition does not have any irritation, allergy and hemolysis. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] Figure 1 This is a photo of the in vitro hemolytic test in Example 1;
[0027] Figure 2 This is a photo of the original drug's in vitro hemolytic test;
[0028] Figure 3 Example 1 Negative control side - stop taking for 72h
[0029] Figure 4 Example 1 Test sample side - drug withdrawal for 72h
[0030] Figure 5 Original drug negative control side - stop drug for 72h
[0031] Figure 6 Original drug test product side - stop taking for 72 hours
[0032] Figure 7 Example 1 Test sample side - 14 days recovery
[0033] Figure 8Original drug reference preparation side - recovery 14 days
[0034] In the figure:
[0035] Figure 1 Analysis: After centrifugation, the supernatant of the positive control tube (DW2) was clear red, and a small amount of red blood cells remained at the bottom of the tube, indicating hemolysis; the red blood cells of the negative control tube (NS2) and the test tubes (C1~C5) were located at the bottom of the test tubes, and the supernatant was colorless and transparent, and no hemolysis occurred.
[0036] Figure 2 Analysis: After centrifugation: the supernatant of the positive control tube (DW3) was clear red, and a small amount of red blood cells remained at the bottom of the tube, indicating hemolysis; the red blood cells of the negative control tube (NS3) and the test tubes (E1~E5) were located at the bottom of the test tubes, and the supernatant was colorless and transparent, and no hemolysis occurred.
[0037] Figure 3 Analysis: No erythema, no obvious abnormalities were found.
[0038] Figure 4 Analysis: No erythema, no obvious abnormalities were found.
[0039] Figure 5 Analysis: No erythema, no obvious abnormalities were found.
[0040] Figure 6 Analysis: Obvious tissue erythema appears, which is irritating.
[0041] Figure 7 Analysis: No erythema, no obvious abnormalities were found.
[0042] Figure 8 Analysis: Obvious tissue erythema appears, which is irritating. DETAILED DESCRIPTION
[0043] The present invention will be described in detail below by way of examples. The following examples are only used to illustrate the present invention, and the present invention is not limited thereto.
[0044] Example 1
[0045] The prescription composition of Eribulin Mesylate Injection is:
[0046]
[0047] Preparation method of Eribulin Mesylate Injection:
[0048] 1) Preparation:
[0049] ① Preparation of sodium hydroxide solution: weigh 2.00g of sodium hydroxide, add 18.00g of water for injection, stir evenly to make its mass fraction 10%.
[0050] ② Add 90.00g of water for injection into the preparation tank, heat to 30°C, keep constant temperature, then add 0.05g of sodium metabisulfite, 0.10g of eribulin mesylate and 0.10g of tromethamine, stir to dissolve, use 10% sodium hydroxide solution to adjust the pH of the mother liquor to 7.2-7.8, add water for injection to the full amount, and fill with nitrogen throughout the preparation process.
[0051] 2) Filtration: Three-stage filtration, the intermediate product is first filtered through a 0.45μm pleated cartridge polypropylene filter, and then filtered through a 0.22μm pleated cartridge polypropylene filter.
[0052] 3) Filling: Fill the drug solution into a 2 mL colorless medium borosilicate glass tube injection bottle, and use a bromobutyl rubber stopper for injection preparations to stopper the bottle. The filling volume of each bottle is 2.10 to 2.15 mL.
[0053] 4) Sterilization: Sterilization was performed by overkill method with the sterilization parameters being 121°C for 15 minutes.
[0054] 5) Leak detection: High voltage discharge method is used, the parameters are host speed 300-400 pieces / minute, station voltage 17500V, and station threshold 827μA.
[0055] 6) Packaging: Pack the qualified preparations, 1 piece / box.
[0056] Comparative Example 1
[0057] This comparative example was prepared according to the information published in CN105640935A, and the specific preparation method is as follows:
[0058]
[0059] Preparation process:
[0060] 1) Weigh sodium chloride, add citrate buffer, and add appropriate amount of water for injection to dissolve completely;
[0061] 2) adding 0.1% medicinal charcoal by volume of water for injection, heating for 5 minutes to remove pyrogens, filtering to remove charcoal, and obtaining a filtrate;
[0062] 3) Cool to 40-50°C, add eribulin mesylate, dissolve, add water for injection to the full amount, and adjust the pH to 5.5-7.0 with citric acid solution or sodium hydroxide solution if necessary;
[0063] 4) The obtained solution is finely filtered through a mixed cellulose ester microporous filter membrane to obtain a filtrate, which is sealed in an ampoule and sterilized by hot pressing at 121° C. for 15 minutes to obtain a finished product of eribulin mesylate injection.
[0064] Experimental Results and Discussion
[0065] 1. Results of the complete preparation inspection
[0066] Example 1 and Comparative Example 1 were compared before and after sterilization. The specific research data are shown in Table 1.
[0067] Table 1 Comparison of product quality before and after sterilization using overkilling method
[0068]
[0069]
[0070] Summary: According to the above test results, when the sterilization parameters of the overkill method (F0>12) were also used for sterilization, the comparative example changed color, but the test items of Example 1 did not change before and after sterilization, indicating that the eribulin mesylate injection composition described in the present invention can tolerate overkilling, thereby ensuring the sterility of the product and meeting the current national bureau guidelines.
[0071] 2. Stability study
[0072] The stability sample of the Eribulin mesylate injection prepared in Example 1 was retained under long-term conditions (temperature 30±2° C., relative humidity 65±5%). The physical and chemical test results are shown in Table 2.
[0073] Table 2 Stability data of Example 1 under long-term conditions
[0074]
[0075]
[0076] Summary: According to the above test results, the various test indicators of the eribulin mesylate injection composition of the present invention met the quality standard requirements under long-term conditions for 24 months, indicating that the proposed prescription has excellent stability.
[0077] 3. Safety research
[0078] With reference to the Technical Guidelines for Drug Irritation, Allergy and Hemolysis Studies published by the Drug Review Center of the State Food and Drug Administration, experiments were designed to compare the animal safety of the original preparation and the preparation of Example 1. The main research contents included a hemolysis test, a guinea pig systemic active allergy test, a rat passive skin allergy test, and a rabbit muscle irritation test.
[0079] (1) Hemolysis test
[0080] According to the Technical Guidelines for Drug Irritation, Allergy and Hemolysis Research issued by CDE in May 2014, injections must undergo hemolysis tests. According to the experimental requirements of the guidelines, the experimental study was conducted. The heart blood of a male rabbit weighing 2.726 kg was selected, and then the original preparation and the preparation of Example 1 were added to observe the hemolysis phenomenon. The experimental data are detailed in Table 3-1, and the hemolysis photos are detailed in Figure 1-2 .
[0081] Table 3-1 Observation results of hemolytic test
[0082]
[0083]
[0084] Note: “+” means hemolysis, “O” means partial hemolysis, “-” means no hemolysis, and “±” means coagulation
[0085] Summary: Example 1 did not cause hemolysis and red blood cell aggregation reaction, and the hemolytic test was qualified, which was consistent with the original drug.
[0086] (2) Guinea pig systemic active allergy test
[0087] According to the requirements of the guidelines, an active allergy test on guinea pigs was conducted. The experimental results are detailed in Tables 3-2 and 3-3.
[0088] Table 3-2 Observation of the incidence and severity of systemic allergic reactions after stimulation on the 14th day after the last sensitization
[0089]
[0090] Table 3-3 Observation on the incidence and severity of systemic allergic reactions after stimulation on the 21st day after the last sensitization
[0091]
[0092] Summary: The results showed that the negative control group, Example 1 group and the original drug group did not show allergic reaction symptoms within 3 hours after the last sensitization on the 14th day and the 21st day, and the allergic reaction incidence was 0%, which was determined to be negative for allergic reaction. The positive control group showed allergic reaction symptoms immediately after the stimulation, and the allergic reaction incidence was 100%.
[0093] (3) Passive skin allergy test in rats
[0094] According to the requirements of the guidelines, an active allergy test on guinea pigs was conducted. The experimental results are detailed in Table 3-4.
[0095] Table 3-4 Blue spot determination in rat passive skin allergy test
[0096]
[0097] Note: Positive rate (%) = {number of rats with blue spots in the inner layer of the skin larger than 5 mm in diameter (number of rats) ÷ number of animals in the group (number of rats)} × 100%
[0098] Summary: The results of this study showed that the passive skin allergy test result of Example 1 was negative, while the original drug showed skin allergy.
[0099] (4) Rabbit vascular irritation test
[0100] According to the guidelines, a rabbit vascular irritation experiment was conducted. The experimental results are shown in Tables 3-5. Microscopic photos of the changes in rabbit vascular tissue after 72 hours of administration and after the recovery period are shown in the attached Figure 3 ~Attached Figure 8 .
[0101] Table 3-5 Determination of vascular irritation intensity in rabbit vascular irritation test
[0102]
[0103] Summary: The eribulin mesylate injection prepared in Example 1 has no irritation to rabbit blood vessels; the original drug has moderate to mild irritation to rabbit muscles, which can be restored by drug discontinuation.
[0104] 4. Summary and discussion
[0105] According to the above results, under the premise of meeting the drug standards, the eribulin mesylate injection composition and preparation process of the present invention can not only tolerate overkill, have good quality stability, almost no animal irritation, simple production process operation, easy control, low requirements on equipment and preparation conditions, and low production cost, but also, compared with the original drug, it has no irritation to blood vessels and less skin allergic reactions, which greatly improves the sterility assurance and clinical safety of the drug, and overcomes the difficulties of eribulin mesylate injection that cannot tolerate overkill, thermal instability and strong animal irritation.
Claims
1. An eribulin mesylate injection composition, characterized in that: The composition of each 100 mL of the composition liquid is: 0.095-0.105 g of eribulin mesylate, 0.095-0.105 g of tromethamine, 0.03-0.07 g of sodium pyrosulfite, 0.98-1.08 g of sodium hydroxide and 98.64-98.80 g of water for injection.
2. The method for preparing the eribulin mesylate injection composition according to claim 1, characterized in that: Taking 100mL volume as an example, the process includes the following: 1) Add 0.03-0.07 g of sodium metabisulfite, 0.095-0.105 g of eribulin mesylate and 0.095-0.105 g of tromethamine to 90.00-95.00 g of water for injection and stir to dissolve; 2) using sodium hydroxide solution to adjust the pH value of the mother liquor; 3) Add water for injection to the full amount, and fill with protective gas throughout the preparation process; 4) Filtration, filling, sterilization, leak detection and packaging.
3. The method for preparing an eribulin mesylate injection composition according to claim 2, characterized in that: The pH value is 7.2-7.
8.
4. The method for preparing an eribulin mesylate injection composition according to claim 2, characterized in that: The liquid preparation temperature is 20-30° C.; the sodium hydroxide concentration is 8%-12%; and the protective gas includes nitrogen.
5. The method for preparing an eribulin mesylate injection composition according to claim 2, characterized in that: The filtration is a three-stage folded filter element filtration, and the filter element material is polyethersulfone or polypropylene.
6. The method for preparing an eribulin mesylate injection composition according to claim 2, characterized in that: The sterilization is moist heat sterilization with a parameter of 121° C. for 15 min.
7. The method for preparing an eribulin mesylate injection composition according to claim 2, characterized in that: The leak detection method is a high-voltage discharge method, and the parameters are a host speed of 300 to 400 pieces per minute, a station voltage of 17500V, and a station threshold of 827μA.
8. The method for preparing an eribulin mesylate injection composition according to claim 2, characterized in that: The packaging material is a 2 mL colorless medium borosilicate glass tube injection bottle; the rubber stopper material is a bromobutyl rubber stopper for injection preparations.
Citation Information
Patent Citations
Eribulin mesylate pharmaceutical composition for injection
CN105640935A
Useful macrocyclization reactions and intermediates in the synthesis of spongein B analogues
CN105683198B
Projection lens apparatus and rear projection type image display apparatus used the same
CN1700048A
Injection containing eribulin and pharmaceutically acceptable salt thereof
CN110545808A
Pharmaceutical composition for treating tumor
US20210023047A1
